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Abstract
Background: CTLA-4 functions primarily as an inhibitor of T cell activation. There are several
candidate explanations as to how CTLA-4 modulates T cell responses, but the exact mechanism
remains undefined. The tail of CTLA-4 does not have any intrinsic enzymatic activity but is able to
associate with several signaling molecules including the serine/threonine phosphatase PP2A. PP2A
is a heterotrimeric molecule comprised of a regulatory B subunit associated with a core dimer of
a scaffolding (A) and a catalytic (C) subunit.
Results: Here, we performed an analysis of the human CTLA-4 interface interacting with PP2A.
We show that PP2A interacts with the cytoplasmic tail of CTLA-4 in two different sites, one on
the lysine rich motif, and the other on the tyrosine residue located at position 182 (but not the
tyrosine 165 of the YVKM motif). Although the interaction between CTLA-4 and PP2A was not
required for inhibition of T cell responses, it was important for T cell activation by inverse agonists
of CTLA-4. Such an interaction was functionally relevant because the inverse agonists induced IL-
2 production in an okadaic acid-dependent manner.
Conclusion: Our studies demonstrate that PP2A interacts with the cytoplasmic tail of human
CTLA-4 through two motifs, the lysine rich motif centered at lysine 155 and the tyrosine residue
182. This interaction and the phosphatase activity of PP2A are important for CTLA-4-mediated T
cell activation.
Background
Cytotoxic T lymphocyte associated antigen-4 (CTLA-4,
CD152) is an activation-induced glycoprotein of the
Immunoglobulin superfamily, whose primary function is
to down-regulate T cell responses [1-4]. CTLA-4 shares its
two known endogenous ligands, the B7 molecules B7.1
(CD80) and B7.2 (CD86), with the costimulatory recep-
tor CD28 [5-7]. Several mechanisms, including antago-
nism of CD28-dependent costimulation and direct
negative signaling have been documented to explain the
inhibitory capacity of CTLA-4 [8]. Since the cytoplasmic
tail of CTLA-4 lacks intrinsic enzymatic activity, the deliv-
ery of such a negative signal is likely provided through the
association of CTLA-4 with key signaling molecules [4].
CTLA-4 has been shown independently by two groups to
associate with the serine/threonine phosphatase PP2A
[9,10]. PP2A is a heterotrimeric holoenzyme which is
comprised of a regulatory B subunit associated with a core
dimer of a scaffolding A subunit (PP2AA) and a catalytic
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all cellular proteins and provides the majority of serine/
threonine phosphate activity within eukaryotic cells [12].
Using recombinant proteins, it has been reported that
PP2AA interacts with the lysine rich motif located in the
juxtamembrane region of the cytoplasmic tail of human
CTLA-4, while the C subunit is thought to interact with
the tyrosine residue in the YVKM motif located at position
165 [9,10]. However, it is currently unknown whether
some of these associations occur in vivo in T cells and if so
what the functional consequences are.
We have previously reported that PP2A may regulate the
ability of CTLA-4 to act as an inhibitor. Newly synthesized
CTLA-4 becomes associated with PP2AA and remains
associated when expressed on the cell surface, effectively
blocking its inhibitory function [10]. Following
TCR:CTLA-4 co-ligation, where CTLA-4 engages B7 mole-
cules expressed on antigen-presenting cells (APCs), PP2A
is phosphorylated and dissociates from CTLA-4, and this
dissociation correlates with the attenuation of T cell acti-
vation [10]. Additionally, CTLA-4-dependent inhibition
of Akt, a downstream target of PP2A, is sensitive to the
PP2A inhibitor okadaic acid, implying that PP2A plays an
important role in CTLA-4-mediated T cell inactivation
[13].
Under unique circumstances, some recombinant ligands
of CTLA-4 can act as inverse agonists making CTLA-4
capable of activating T cells by itself, independent of TCR
or CD28 ligation [14,15]. We have recently shown that
soluble B7.1 Ig or 24:26, a bispecific, in-tandem single-
chain Fv (ScFv) against human CTLA-4, function as
inverse agonists of CTLA-4 resulting in the activation of
primary human T cells and T cell lines. Such an inverse
agonist activity correlates with the ability to induce the
formation of a unique dimer-based CTLA-4 oligomer that
signals through its cytoplasmic tail [15]. Under these con-
ditions of ligation, we have observed an increased associ-
ation between PP2A and CTLA-4 suggesting that CTLA-4
may also induce T cell activation in a PP2A-dependent
manner [14].
As suggested by Rudd, the role of PP2A in CTLA-4 func-
tion needs clarification [16]. Here, we started to address
this issue by showing for the first time that the association
between CTLA-4 and PP2A occurs in primary human T
cells, suggesting that this interaction is physiologically rel-
evant. Furthermore, we characterized the CTLA-4 interface
interacting with PP2A using a panel of stably transfected
Jurkat T cells expressing either wildtype (WT) CTLA-4 or
CTLA-4 molecules mutated at various residues within the
cytoplasmic domain. In this way, we eliminated any con-
founding effects as Jurkat T cells do not express endog-
enous CTLA-4 [17]. Our results confirm the importance of
the lysine rich motif for the association of PP2AA. How-
ever, contrary to previous studies, we report that not the
first but the second tyrosine residue located at position
182 of human CTLA-4 is important for the binding of
PP2AC to CTLA-4. Functionally, an increase in the associ-
ation of PP2A to CTLA-4 was observed under conditions
of inverse agonist ligation of CTLA-4 molecules with the
exception of those mutated at the lysine residues. Such an
increase correlated with the ability of CTLA-4 to induce T
cell activation, and was dependent on the enzymatic activ-
ity of PP2A.
Results
CTLA-4 interacts with PP2A in primary human T cells
The interaction between CTLA-4 and PP2A has previously
been shown by yeast two hybrid analysis and transfected
cell lines [9,10]. However, this association has not been
confirmed in primary T cells. Thus, we first explored this
interaction using peripheral blood mononuclear cells
(PBMC) isolated from healthy donors and cultured in the
presence of PMA and ionomycin for 72 h to induce the
expression of CTLA-4. The cells were washed and rested in
fresh media for an additional 24 h before cell lysates were
immunoprecipitated using anti-CTLA-4 antibodies (Abs)
and immunoblotted for CTLA-4, PP2AA and PP2AC. As
shown in figure 1A, both the scaffolding unit and the cat-
alytic unit of PP2A (PP2AA and PP2AC, respectively),
which together form the core PP2A enzyme, co-precipi-
tated with CTLA-4 in primary T cells.
To gain insight into the interaction between CTLA-4 and
PP2A we needed to use a feasible model system in which
CTLA-4 interacts with PP2A in primary human T cells and Jurkat T cellsFigure 1
CTLA-4 interacts with PP2A in primary human T 
cells and Jurkat T cells. A) PBMC were isolated from 
healthy donors and cultured in the presence of PMA (1 ng/
ml) and ionomycin (100 ng/ml) for 72 h. The cells were 
washed extensively and rested for 24 h in fresh media. Cell 
lysates were immunoprecipitated using anti-CTLA-4 Abs and 
immunoblotted for CTLA-4, PP2AA and PP2AC. B) Jurkat T 
cells stably transfected with WT CTLA-4 were cultured 
overnight in the presence of doxycycline (1 μg/ml) to induce 
the expression of CTLA-4. Cell lysates were immunoprecipi-
tated and immunoblotted as in A).Page 2 of 10
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4 molecules in the absence of endogenous CTLA-4 and
assay for their association with PP2A. Therefore, we exam-
ined the CTLA-4:PP2A association in Jurkat T cells that
had been stably transfected with WT CTLA-4 under the
control of a doxycycline inducible promoter. We have pre-
viously reported that these cells lack expression of endog-
enous CTLA-4, thus eliminating any masking effect on the
results [17]. After overnight culture in the presence of dox-
ycycline to induce the expression of CTLA-4, lysates from
these transfected Jurkat T cells were prepared and subse-
quently immunoprecipitated using anti-CTLA-4 Abs (Fig-
ure 1B). As seen in PBMC, WT CTLA-4 associated with
PP2AA and PP2AC, indicating that this model system is
appropriate to perform a structure:function analysis of the
CTLA-4 interface interacting with PP2A.
Surface expression of WT and mutant CTLA-4 molecules
To dissect the interaction between CTLA-4 and PP2A we
used a panel of doxycycline-inducible Jurkat T cells stably
transfected with WT CTLA-4 or CTLA-4 molecules con-
taining mutations within the cytoplasmic domain. The
intracellular tail of CTLA-4 is 100% conserved among
mammalian species suggesting that this domain is impor-
tant for the function of CTLA-4 [18]. Although the intrac-
ellular portion of CTLA-4 does not have any intrinsic
enzymatic activity, it contains several motifs that may be
important for its interaction with key signaling molecules
[4]. Thus, we examined CTLA-4 molecules containing
mutations at each of these putative motifs. These included
the lysine rich motif (KLESS) located in the juxtamem-
brane region of the tail and the tyrosine residue located at
position 165 (Y165F), both sites previously claimed to be
important for the interaction with PP2A [9,10]. CTLA-4
molecules with mutations at the second tyrosine residue
(Y182F), at both tyrosine residues (Y165F/Y182F), and at
the proline rich domain (PRO-) located at residues 169–
173 were also used. These Jurkat T cell lines were cultured
overnight with doxycycline to induce the expression
CTLA-4. The surface expression of each CTLA-4 variant
was measured by flow cytometry (Figure 2). Similar levels
of surface expression were observed for cells expressing
WT (mean fluorescence intensity (MFI), 691), PRO- (MFI,
330) and Y182F (MFI, 432) CTLA-4 molecules. Lower lev-
els of surface expression were detected for KLESS CTLA-4
(MFI, 43), while an increase in the level of CTLA-4 on the
surface was observed for cells expressing molecules
mutated at position Y165 (both Y165F (MFI, 1772), and
Y165F/Y182F(MFI, 1757)), likely owing to their inability
to be effectively internalized by AP-2 [19-21].
PP2A interacts with CTLA-4 at lysines 152, 155 and 156 
and tyrosine 182
PP2A is a heterotrimeric complex comprised of a core
dimer consisting of the A and C subunits and a regulatory
B subunit thought to provide substrate specificity and/or
localization within the cell [11]. Previous reports have
demonstrated that CTLA-4 can interact with both the A
and C subunits of PP2A [9,10]. Using our panel of CTLA-
4 mutants we performed a structural analysis of the asso-
ciation of both PP2AA and PP2AC subunits with CTLA-4.
To do this, we induced the expression of the different
CTLA-4 mutants, immunoprecipitated PP2A using anti-
PP2AA or anti-PP2AC Abs and immunoblotted for CTLA-
4 (Figure 3). Under these conditions the amount of
immunoprecipitated PP2A represents approximately
1.5% of total PP2A. Equal loading was confirmed by blot-
ting for the immunoprecipitating Ab. As expected, we
observed co-precipitation of both PP2AA and PP2AC with
WT CTLA-4. On average approximately 2% of total CTLA-
4 immunoprecipitated with PP2A. As it is the surface pool
of CTLA-4 (representing approximately 10% of total
CTLA-4) that associates with PP2A, we estimate that
approximately 20% of surface CTLA-4 is associated with
PP2A. Additionally, CTLA-4 variants mutated at the pro-
line rich motif were able to co-precipitate with PP2A at
Sequence and surface expression CTLA-4 molecules used in these studiesFig re 2
Sequence and surface expression CTLA-4 molecules 
used in these studies. The WT sequence of the intracellu-
lar tail of CTLA-4 is shown in full with key residues targeted 
for mutation depicted in bold. Lysine residues 152, 155 and 
156 were changed to alanine residues to generate KLESS 
CTLA-4. Tyrosine residues located at positions 165 or 182 
have been converted to phenylalanine to create Y165F 
CTLA-4 and Y182F CTLA-4, respectively. The double 
mutant Y165F/Y182F CTLA-4 contains mutations at both 
tyrosine residues. PRO- CTLA-4 contains mutations of pro-
line residues 169 and 173 to alanine residues. Stably trans-
fected Jurkat T cell lines have been generated for each of 
these CTLA-4 variants. Cells were induced overnight with 
doxycycline (1 μg/ml) and the surface expression of CTLA-4 
was measured by flow cytometry (black line, CTLA-4; shaded 
profile, isotype-matched Ab).Page 3 of 10
(page number not for citation purposes)
BMC Immunology 2009, 10:23 http://www.biomedcentral.com/1471-2172/10/23similar levels compared to WT CTLA-4, suggesting that
these residues are not essential in the CTLA-4:PP2A inter-
action.
As expected [10], KLESS CTLA-4 molecules failed to inter-
act with PP2AA (Figure 3A). The association between
PP2AC and KLESS CTLA-4 was also significantly dimin-
ished (Figure 3B). This result correlated with the observa-
tion that in vivo PP2AA is always found in association with
PP2AC, suggesting that intact binding sites for both subu-
nits may be required to establish a stable interaction
between PP2A and CTLA-4. Surprisingly, we found that
Y165F CTLA-4 associated with PP2AA and PP2AC at sim-
ilar levels compared to WT CTLA-4, implying that this res-
idue may not be the main putative binding site for the
catalytic subunit of PP2A as previously reported [9]. Alter-
natively, the second tyrosine residue in the cytoplasmic
tail (Y182) may provide a non-canonical binding site for
PP2AC in the absence of Y165 because mutation of tyro-
sine 182 prevented the interaction between CTLA-4 and
PP2A (Figure 3A, B). Similarly, the double tyrosine
mutant, Y165F/Y182F failed to interact in vivo with PP2A,
further corroborating the key role of the Y182 as the puta-
tive primary binding site for the catalytic subunit of PP2A.
Effect of mutations in the intracellular domain of CTLA-4 
on its inhibitory function
We have previously shown that PP2A plays a role as a neg-
ative regulator of the inhibitory function of CTLA-4, its
primary function in vivo [10]. Therefore, we next deter-
mined the ability of each of the CTLA-4 variants examined
above to attenuate T cell responses against the staphyloco-
ccal enterotoxin E (SEE) superantigen. Jurkat T cell lines
containing the mutant CTLA-4 constructs were cultured
overnight with or without doxycycline to induce the
expression of CTLA-4 and were then stimulated in the
presence of APC expressing B7 molecules on their surface
and SEE at the indicated concentrations at 37°C for 24
hours (Figure 4A). The maximal level of inhibition was
determined for each CTLA-4 variant by calculating the
percent of IL-2 produced in the presence of CTLA-4
expression compared to cells stimulated in the absence of
CTLA-4 induction. WT CTLA-4 as well as each mutant
CTLA-4 was functionally able to inhibit T cell responses
(Figure 4A). Cells expressing WT CTLA-4 attenuated IL-2
production in response to SEE stimulation by 65% on
average. IL-2 production was inhibited between 68–78%
by cells expressing CTLA-4 molecules with mutations in
the lysine rich domain and the tyrosine 165 residue
(KLESS, Y165F and Y165F/Y182F CTLA-4), while PRO-
and Y182F CTLA-4 variants abrogated the response by
41% and 46%, respectively. The ability of each CTLA-4
variant to inhibit T cell responses suggests that the interac-
tion between CTLA-4 and PP2A is not in itself the deter-
minant of the inhibitory function of CTLA-4 and that
there are additional factors that play a role in mediating
this function.
One potential target of the interplay between CTLA-4 and
PP2A may be CD28. As previously shown [15], we found
that CD28 expression was required for CTLA-4-mediated
inhibition (Figure 4B). CD28+ or CD28- Jurkat cells were
cultured overnight with doxycycline to induce the expres-
sion of Y165F CTLA-4 and further stimulated with
SEE:APC. IL-2 production was inhibited by CTLA-4 in
cells expressing CD28. Such an inhibition of the response
PP2A interacts with CTLA-4 through the lysine rich domain and tyrosine 182Figure 3
PP2A interacts with CTLA-4 through the lysine rich 
domain and tyrosine 182. A) Association of CTLA-4 with 
the A subunit of PP2A. Jurkat T cell lines stably transfected 
with CTLA-4 variants were cultured overnight in the pres-
ence of doxycycline (1 μg/ml) to induce the expression of 
CTLA-4. Cell lysates were prepared and used for immuno-
precipitation of PP2AA, followed by immunoblotting for 
CTLA-4, PP2AA and PP2AC. B) Association of CTLA-4 with 
the C subunit of PP2A. Jurkat cells were cultured and lysed 
as in A) and used for immunoprecipitation of PP2AC, fol-
lowed by blotting for CTLA-4, PP2AA and PP2AC. Beads, 
immunoprecipitating Ab without cell lysate. Blots are repre-
sentative of at least 3 independent experiments.Page 4 of 10
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amount of activation was significantly lower. However,
reconstitution of CD28- T cells expressing CTLA-4 with
CD28 restored the inhibitory function of CTLA-4. This
suggests that the inhibitory function of CTLA-4 requires
the expression of CD28 indicating that CTLA-4 may likely
act on the CD28 signaling pathway.
The CTLA-4:PP2A interaction is required for the response 
to inverse agonists of CTLA-4
Although the primary function of CTLA-4 is to inhibit T
cell activation, we have recently shown that CTLA-4 has an
inherent signaling plasticity. This plasticity is revealed by
inverse agonists of CTLA-4 that can induce T cell activa-
tion by themselves in the absence of TCR engagement and
CD28 costimulation [14,15]. As our panel of CTLA-4 var-
iants contains mutations at key residues within the tail, it
was ideal to determine the importance of these motifs in
the response to inverse agonists of CTLA-4. To do this, we
induced expression of CTLA-4 with doxycycline and stim-
ulated the T cells with 24:26 at 37°C for 48 hours. IL-2
production was used as a readout for CTLA-4-dependent
T cell activation (Figure 5). Engagement of WT CTLA-4
with 24:26 induced significant IL-2 production compared
to unstimulated cells (Figure 5A). T cells expressing KLESS
CTLA-4, a molecule that lacks association with PP2A,
failed to respond to the inverse agonist 24:26, suggesting
that PP2A binding to the lysine motif is important for the
activating function of CTLA-4 (Figure 5B). The amount of
IL-2 produced increased in a dose dependent manner
upon ligation of PRO- CTLA-4, indicating that the proline
residues are not essential for T cell activation by CTLA-4
inverse agonists (Figure 5D). 24:26 binding to Y165F
Inhibitory function of CTLA-4 molecules with mutation in the cytoplasmic domainFigure 4
Inhibitory function of CTLA-4 molecules with muta-
tion in the cytoplasmic domain. A) Jurkat T cells stably 
transfected with WT CTLA-4 or mutant CTLA-4 constructs 
were cultured overnight in the absence or presence of doxy-
cycline (1 μg/ml). Cells were further stimulated with APCs 
and SEE (1 and 10 ng/ml) for 24 hours at 37°C. IL-2 produc-
tion was measured by ELISA. Inhibition of IL-2 was deter-
mined for each CTLA-4 variant by calculating the percent of 
IL-2 produced in the presence of CTLA-4 expression nor-
malized to the maximal IL-2 level in the absence of CTLA-4 
at each concentration of SEE. The maximal level of inhibition 
was plotted for each CTLA-4 variant. This graph was gener-
ated using triplicate data for each concentration of SEE, from 
three independent experiments. B) CD28 expression is 
required for CTLA-4 mediated inhibition. CD28+, CD28- and 
CD28-reconstituted Jurkat T cells were cultured overnight 
without (black squares) or with doxycycline (1 μg/ml) (black 
triangles) to induce the expression of Y165F CTLA-4. Cells 
were stimulated with SEE:APC and IL-2 was measured as in 
A). **, p < 0.01; ***, p < 0.001.
The ability of CTLA-4 to activate T cells correlates with its int r ction with PP2AFigure 5
The ability of CTLA-4 to activate T cells correlates 
with its interaction with PP2A. Stably transfected Jurkat 
T cells were induced overnight with doxycycline (1 μg/ml) to 
express A) WT CTLA-4, B) KLESS CTLA-4, C) Y165F 
CTLA-4, D) PRO- CTLA-4, E) Y182F CTLA-4 or F) Y165F/
Y182F CTLA-4. Cells were stimulated in triplicate in the 
presence of doxycycline with the indicated concentrations of 
24:26 for 48 hours at 37°C. Supernatants were harvested 
and IL-2 was measured by ELISA. All data are representative 
of three independent experiments. **, p < 0.01; ***, p < 
0.001.Page 5 of 10
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other CTLA-4 variants (Figure 5C). In contrast, CTLA-4
molecules mutated at Y182 showed a reduced ability to
activate T cells when engaged with an inverse agonist com-
pared to Y165F CTLA-4, suggesting that this residue may
also be important for the activating function of CTLA-4
although less that the lysine-rich motif (Figure 5E). How-
ever, T cell activation by inverse agonists of CTLA-4 was
practically abolished when both tyrosine residues were
absent compared to CTLA-4 molecules mutated at either
tyrosine residue alone, indicating that the both tyrosine
residues may provide some functional redundancy with
respect to inverse agonist activity (Figure 5F). Based on
these biochemical and functional results, we concluded
that the residues that are important for the association of
PP2A to CTLA-4 are K152, 155 and156 and Y182, and that
this association is required for the inverse agonist
responses of CTLA-4.
The association of PP2A to CTLA-4 is increased by inverse 
agonists of CTLA-4
We have previously reported that 24:26 binding to Y165F
CTLA-4 stabilizes the association between PP2A and
CTLA-4 [14]. Knowing the CTLA-4 residues involved in
the interaction with PP2A allowed us to determine the
molecular basis of such an increased association. To do
this, we cultured the transfected T cell lines overnight in
the presence of doxycycline to induce the expression of
each CTLA-4 variant. T cells were then stimulated with
24:26 at 37°C for 60 minutes, lysed, immunoprecipitated
with anti-PP2AA Abs and subsequently immunoblotted
for CTLA-4. Immunoblotting for PP2AA and PP2AC was
used as controls. We observed an increase in the amount
of CTLA-4 co-precipitated with PP2AA following 24:26
engagement of WT CTLA-4 (Figure 6A), Y165F CTLA-4
(Figure 6C), and PRO- CTLA-4 (Figure 6D), correlating
with the ability to induce T cell activation under similar
stimulation conditions. In contrast, ligation of KLESS
CTLA-4 with 24:26 was unable to induce co-precipitation
with PP2AA (Figure 6B). Although little or no association
was detected between PP2AA and Y182F CTLA-4 or
Y165F/Y182F CTLA-4 in unstimulated conditions, a small
increase in the level of association was seen upon inverse
agonist ligation of these CTLA-4 molecules (Figure 6E, F).
This low level of association correlated with the ability of
Y182F CTLA-4 and Y165F/Y182F CTLA-4 to induce some
IL-2 production when engaged with the inverse agonist
24:26, respectively.
The inverse agonist properties of CTLA-4 are dependent 
on the phosphatase activity of PP2A
We and others have shown that inhibition of T cell activa-
tion by CTLA-4 requires PP2A activity [10,13]. Specifi-
cally, CTLA-4 inhibits the activation of Akt, a molecule
that is important in many cellular processes including IL-
2 production [22]. CTLA-4-mediated inhibition of Akt
activity is dependent on the phosphatase activity of PP2A
as Akt phosphorylation was shown to be sensitive to the
PP2A inhibitor okadaic acid (OA) [13]. Thus, we deter-
mined whether the activity of PP2A was important for the
inverse agonist properties of CTLA-4. The panel of stably
transfected Jurkat T cells was induced overnight in the
presence of doxycycline to induce the expression of the
CTLA-4 variants. The cells were further cultured with dox-
ycycline and stimulated with 24:26 in the presence or
24:26 increases the interaction of CTLA-4 with PP2AFigure 6
24:26 increases the interaction of CTLA-4 with 
PP2A. Stably transfected Jurkat T cells were induced over-
night with doxycycline (1 μg/ml) to express A) WT CTLA-4, 
B) KLESS CTLA-4, C) Y165F CTLA-4, D) PRO- CTLA-4, E) 
Y182F CTLA-4 or F) Y165F/Y182F CTLA-4. The cells were 
stimulated with or without 24:26 (100 μg/ml) for 60 minutes 
at 37°C. Cells were washed then lysed in standard lysis 
buffer containing Triton X-100 (1%). Lysates were used for 
immunoprecipitation of PP2AA, and subsequently blotted for 
CTLA-4, PP2AA and PP2AC. All data is representative of at 
least two independent experiments.Page 6 of 10
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malized to the amount of IL-2 produced in the absence of
OA for each of the CTLA-4 variants. We found that CTLA-
4-mediated T cell activation was significantly inhibited by
OA in T cells expressing WT and mutants forms of CTLA-
4 excluding KLESS (Figure 7). Inhibition of inverse ago-
nist activation by OA ranged from 45% (for Y165F/
Y182F) to 88% (for Y182F) (69% for WT, 70% for PRO-,
and 76% for Y165F). As shown above (Figure 5), KLESS
CTLA-4 did not respond to 24:26 and thus no effect of OA
was apparent (Figure 7). These results suggest that the
phosphatase activity of PP2A is required for the inverse
agonist response of CTLA-4.
Discussion and conclusion
Understanding the mechanism of CTLA-4 function has
proved to be remarkably puzzling over the past two dec-
ades. The ability of CTLA-4 to down-regulate T cell activa-
tion has been well established in multiple experimental
systems including knock-out mouse models and T cell
lines [4]. Both extrinsic and intrinsic factors contribute to
the inhibitory mechanism of CTLA-4 in vivo [16]. Antago-
nism of CD28-dependent costimulation provides a plau-
sible explanation for CTLA-4-mediated inhibition since
CTLA-4 has a higher affinity and avidity for their shared
ligands. However, the competition with CD28 for ligands
only occurs when CTLA-4 is expressed at very high levels
on the cell surface, indicating that an alternate mechanism
lends to CTLA-4-dependent T cell inactivation [8]. The
direct delivery of a negative signal provides a more likely
explanation for the inhibitory function of CTLA-4 at early
stages of T cell down-regulation. This mechanism is func-
tional at low levels of CTLA-4 surface expression and
requires an intact cytoplasmic domain. The precise signal-
ing pathway initialized by CTLA-4 is still undefined
although it has been linked to down-regulation of CD28-
dependent events [23]. Many proteins have been shown
to associate with CTLA-4. Among these, the serine/threo-
nine phosphatase PP2A stands out as a candidate that can
affect key molecules downstream of CD28, such as Akt,
thereby affecting essential cellular events [24].
In this study, we dissected the interaction between PP2A
and CTLA-4 both from a structural point of view, to iden-
tify the areas of interaction, as well as from a functional
point of view, to establish the requirement of such an
interaction for the inhibitory and activating effects of
CTLA-4 ligation. This was done using a panel of Jurkat T
cells stably transfected with WT CTLA-4 or CTLA-4 mole-
cules mutated at various locations throughout the intrac-
ellular domain. Previous data from yeast two hybrid
studies suggested that the cytoplasmic domain of mouse
CTLA-4 interacted with two subunits of the core dimer of
PP2A [9,10]. The core dimer is comprised of a scaffolding
A subunit and a catalytic C subunit, each existing as α and
β isoforms. The association of the dimer to a third regula-
tory B subunit provides the cellular localization and target
specificity of PP2A [11]. Recent evidence has determined
that post-translational modification of PP2AC plays an
important role in the B subunit selection [11]. The
requirements for the interaction of PP2A with CTLA-4 in
vivo in human T cells were not identified, justifying the
current study. We confirm here that the K-rich motif
(located at lysine residues 152, 155 and 156) is required
for the interaction of CTLA-4 with PP2A. Mutation of
these residues to alanine (KLESS CTLA-4) abrogated
CTLA-4:PP2A co-precipitation. This confirmed our previ-
ous observation under conditions of equalized expression
of WT CTLA-4 and KLESS CTLA-4, suggesting that the
lower expression of KLESS CTLA-4 in this study is not
likely contributing to its lack of association with PP2A
[10]. This observation is consistent with previous data
pointing to the A subunit as the part of PP2A interacting
with the K-rich motif [10].
The phosphatase activity of PP2A is required for CTLA-4-mediated T cell activationFigure 7
The phosphatase activity of PP2A is required for 
CTLA-4-mediated T cell activation. Stably transfected 
Jurkat T cells were cultured overnight in the presence of 
doxycycline (1 μg/ml) to induce the expression of WT 
CTLA-4 or CTLA-4 mutant molecules. The cells were fur-
ther cultured in the presence of doxycycline and stimulated 
with 24:26 (100 μg/ml) in the presence or absence of OA 
(0.01 μM) for 48 hours at 37°C. Supernatants were har-
vested and IL-2 production was measured by ELISA. For each 
CTLA-4 variant the percent of IL-2 produced in the presence 
of OA was normalized to IL-2 levels in the absence of OA. 
All graphs are representative of at least two independent 
experiments.Page 7 of 10
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cally with murine CTLA-4 in HEK293 cells transfected
with the cytoplasmic domain of CTLA-4 fused to GST, and
the interaction site was suggested to be the tyrosine 165 of
the YVKM motif by yeast two hybrid analysis [9]. How-
ever, confirmation of the Y165 residue as the interaction
site for PP2AC interaction was not examined in mouse or
human T cells. An unexpected finding of our study here is
that in human T cells it is the second tyrosine in the cyto-
plasmic tail of human CTLA-4 and not the first tyrosine
(Y165) that is important for the interaction with PP2AC.
We observed that co-precipitation of PP2A and CTLA-4 in
human T cells was not affected when Y165 was mutated to
phenylalanine. Since the A and C subunit of PP2A are
almost always found associated with each other [12], this
result suggested that either mutating the PP2AC binding
site was not enough to break the CTLA-4:PP2AA interac-
tion or that Y165 was not the essential residue. We found
that both PP2AA and PP2AC were able to co-precipitate
Y165F CTLA-4 molecules, implying that another residue
was likely responsible for interacting with the C subunit of
PP2A. Our data indicate that the key residue for the sec-
ond site of the CTLA-4:PP2AA interaction in human T
cells is Y182. CTLA-4 molecules mutated at this second
tyrosine (Y182F CTLA-4) had severely diminished interac-
tion with PP2A. We cannot exclude that the Y165 may
contribute to this interaction when Y182 is not available
because a small level of association is observed between
Y182F CTLA-4 and PP2A. However, the same level of co-
precipitation is noted when both tyrosine residues are
mutated (Y165F/Y182F CTLA-4) indicating that Y182 is
the important residue for binding PP2AC and that the
small amount of association observed is likely due to the
intact PP2AA binding motif. Based on our results we pro-
pose a model in which the CTLA-4:PP2A interaction
occurs at two distinct binding motifs: one is the lysine-rich
motif binding to the A subunit of PP2A and the other is
the Y182 residue of CTLA-4 binding to the C subunit of
PP2A. This model predicts that the lysine-rich motif is the
primary site responsible for stabilizing the CTLA-4:PP2A
interaction and the tyrosine residues may be less impor-
tant since they may be redundant in their ability to inter-
act with PP2AC. This prediction correlates with the
functional data presented in this study.
From a functional point of view, CTLA-4 displays a remark-
able plasticity as it can inhibit or even activate T cells
depending on the ligand it engages and the conditions in
which this engagement occurs. The primary physiological
function of CTLA-4 is to down-regulate T cell activation. We
have previously reported that, under conditions of TCR and
CTLA-4 co-ligation, PP2A is phosphorylated and dissoci-
ates from CTLA-4 [10]. This correlates with the ability of
CTLA-4 to inhibit T cell activation. This suggested that
PP2A when bound to CTLA-4 prevents rather than medi-
ates the inhibitory function of CTLA-4. In contrast, when
PP2A is dissociated from CTLA-4, it likely inactivates down-
stream targets including Akt, consistent with the observa-
tion that CTLA-4-dependent inhibition of Akt
phosphorylation is sensitive to OA [13]. This model is con-
sistent with the findings reported here that all the CTLA-4
mutants, independently of their ability to bind PP2A,
inhibited IL-2 production when co-ligated with the TCR.
The magnitude of inhibition through CTLA-4 in different
in vitro models, including our own, is relatively modest
(50–70% on average) compared to the striking phenotype
of CTLA-4 knockout mice. This may be due to the use of cell
lines rather than primary cells, to more intense activation
conditions used in the in vitro systems, or other factors.
Still, such an inhibition is reproducible and statistically sig-
nificant. It remains to be determined how such co-ligation
of CTLA-4 and TCR triggers the activity of PP2A.
The other aspect of CTLA-4 function is its ability to activate T
cells when binding recombinant inverse agonist ligands,
such as soluble B7.1 Ig and 24:26. Under these conditions,
PP2A also stands as a key player. We show here that all CTLA-
4 variants capable of interacting with PP2A showed
enhanced association with this phosphatase following
CTLA-4 engagement with 24:26. Such an enhanced associa-
tion is in contrast to the PP2A dissociation observed when
CTLA-4 acts as an inhibitory receptor. This enhanced associ-
ation between CTLA-4 and PP2A is likely the result of stabi-
lization of the interaction between these two molecules. We
have shown that 24:26 induces the formation of dimer-
based CTLA-4 oligomers that are tightly associated with each
other on the T cell surface [15]. The formation of such oli-
gomers may provide a unique structure to facilitate the inter-
action between PP2A and CTLA-4. The enhanced CTLA-
4:PP2A interaction upon inverse agonist ligation correlated
with the ability of CTLA-4 to induce T cell activation. More-
over, the inverse agonist response was sensitive to the protein
phosphatase inhibitor OA as IL-2 production induced upon
24:26 engagement of CTLA-4 was diminished its presence.
Although OA is best known as an inhibitor of PP2A we can
not rule out the inhibition of other phosphatases which may
contribute to CTLA-4-mediated T cell activation. However,
the effect of OA did not completely abolish the ability of
CTLA-4 to induce IL-2 production, likely owing to the consti-
tutive Akt activation in Jurkat T cells [25].
Delineation of the interaction between CTLA-4 and PP2A
provides mechanistic insights into the signaling pathways
targeted by CTLA-4. The costimulatory molecule CD28
has also been shown to associate with PP2A [9,10]. Micro-
array analysis of genes regulated upon B7 ligation of
CTLA-4 suggests that CTLA-4 inhibits T cells by inhibiting
CD28-dependent genes and not TCR-dependent genes
[23]. Furthermore, we have shown that CD28 expression
is essential for the inhibitory and activating function of
CTLA-4 [15]. Therefore, it is plausible that CTLA-4 may
function through PP2A as an inhibitor by blocking CD28Page 8 of 10
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aling pathway. PP2A activity is dependent on its phospho-
rylation state, with unphosphorylated PP2A being active
and phosphorylated PP2A rendered inactive. PP2A is able
to dephosphorylate itself to regain activity [26].
One distinction between the inhibition of T cell activation by
CTLA-4 and the activation of T cells by inverse agonists of
CTLA-4 is that the former does not require the association of
PP2A to CTLA-4 whereas the latter does. However, both
responses are inhibited by okadaic acid [13], implying that
PP2A is a critical mediator of them. We propose that, under
conditions of T cell inhibition, PP2A is phosphorylated and
dissociates from CTLA-4, becoming available to block CD28
signaling. Such a blockade may affect upstream events (eg.,
inhibition of lck, blockade of CD28-PI3K interaction), or
downstream events (eg., direct inhibition of Akt). In this
context, CTLA-4 would act as a shuttle of PP2A to the immu-
nological synapse where, upon release, PP2A could act on
TCR-ζ and CD28 signaling events [27]. It is unclear, how in
our experimental system, CTLA-4 molecules that cannot
bind PP2A can still inhibit T cell activation. Perhaps these
molecules function to inhibit T cell responses primarily by
sequestering B7 molecules from CD28.
Under conditions of T cell activation through CTLA-4, the
pool of PP2A bound to CTLA-4 may trigger TCR-ζ and
CD28 signaling by activating lck [14]. Lck activation,
occurs through dephosphorylation of the negative regula-
tory tyrosine (residue 505) which induces autophosphor-
ylation at tyrosine 394, initiating its kinase activity [28-
30]. In addition to serine/threonine phosphatase acitivity,
it has been reported that PP2A may also have tyrosine
phosphatase activity [24]. Since both the phosphatase
activity of PP2A and lck expression are required for 24:26-
induced T cell activation [14], it is plausible to propose
that PP2A could activate lck and initiate CD28 signaling.
Methods
Cells
Peripheral blood mononuclear cells (PBMC) were isolated
from heparinized blood on Ficoll gradients (Amersham
Pharmacia Biotech, Uppsala, Sweden). PBMC were cul-
tured with 1 ng/ml PMA (Sigma-Aldrich, Oakville, Ontario,
Canada) and 100 ng/ml ionomycin (Sigma-Aldrich) for 72
hours at 37°C, 5% CO2 to induce CTLA-4 expression. Cells
were washed extensively, rested for 24 hours in fresh
medium and used for biochemical experiments.
The stably transfected doxycycline-inducible CTLA-4 Jur-
kat T cell panel used for these studies has been previously
described [10,14,17,27,31]. CD28- cells stably expressing
Y165F CTLA-4 were reconstituted with WT CD28. Stable
transfectant clones were selected in the presence of G418.
The B lymphoblastoid cell line, LG2, used as APC was pro-
vided by Dr. E. Long (National Institute of Allergy and
Infectious Disease, National Institute of Health, Bethesda,
MD). Cells were cultured in RPMI 1640 medium supple-
mented with 10% FCS.
Antibodies and reagents
The mouse monoclonal antibody (Ab) 11 and the ScFv
molecule 24:26, both against human CTLA-4 were gener-
ated at Wyeth Research (Cambridge, MA) and have been
reported previously [4,10,14,17,27,31]. The following
commercially available Abs were used in these studies: a
goat polyclonal antiserum against the serine/threonine
phosphatase 2A (PP2A) Aα (Santa Cruz Biotechnology,
Santa Cruz, CA) and a mouse mAb against the PP2A cata-
lytic subunit (Upstate Biotechnology, Lake Placid, NY. PE-
labeled IgG2a were purchased from eBioscience (San
Diego, CA). PE-labeled anti-human CTLA-4 was pur-
chased from BD Biosciences (San Diego, CA). Staphyloco-
ccal enterotoxin E (SEE) was purchased from Toxin
Technology (Sarasota, FL). Okadaic acid was purchased
from Sigma-Aldrich (Oakville, Ontario, Canada).
T cell functional assays
Doxycycline-induced Jurkat E6.1 T cell transfectants (0.1 ×
106/group) were cultured with or without SEE (1 ng/ml or
10 ng/ml)) or 24:26 at the concentrations indicated, and
plated in triplicate in 96-well plates at 37°C for 24 or 48
hours, respectively [14]. Okadaic acid (0.01 μM) was
added in the indicated experiments. IL-2 in culture super-
natants was measured by ELISA (BD Biosciences).
Flow cytometry
Stably transfected Jurkat T cells were cultured overnight
with doxycycline (1 μg/ml) to induce the expression of
CTLA-4. Cells (1 × 106/group) were washed and stained
with PE-labeled anti-CTLA-4 or isotype matched control on
ice. Samples were then washed in PBS and analyzed by flow
cytometry (Flowjo, Tree Star, Inc., Stanford University).
Biochemistry
Doxycycline-induced Jurkat T cells (30 × 106/group) were
stimulated with or without 24:26 (100 μg/ml) at 37°C for
60 minutes. Primary human T cells (45 × 106/group) were
stimulated with PMA and ionomycin for 72 h, washed
and further rested for 24 h. Cells were subsequently
washed and lysed in standard lysis buffer containing Tri-
ton X-100 (1%). Cell lysates were immunoprecipitated
with dithiobis succinimidyl propionate (DSP) cross-
linked Abs on protein G agarose beads as previously
described [17,32,33]. Protein samples were resolved by
SDS-PAGE and analyzed by Western blotting using a dig-
ital image analyzer (Alpha Innotech).
Statistics
Unpaired Student's t tests were performed using Graph-
Pad Prism software. A difference between groups was con-
sidered significant when p ≤ 0.05.Page 9 of 10
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